8153590: Antidote for factor Xa inhibitor and methods of using the same GL and PBC hold corporate patents: U.S. The specific roles of these authors are articulated in the ‘author contributions’ section.Ĭompeting interests: At the time of the study, all authors were employees and stakeholders of Portola Pharmaceuticals. No one other than the listed authors had control over the data, over how the data were analyzed or interpreted, or over the wording or conclusions used by the authors in the manuscript. The authors have met the ICMJE criteria, participated in the development of the manuscript, agreed to the content, and approved its submission. Currently, all authors, besides PP and SJH, are employees of Portola. The study has been designed, performed, and analysed by all authors who were employees of Portola Pharmaceuticals and received salaries. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: The study has been funded by Portola Pharmaceuticals. Received: NovemAccepted: MaPublished: March 28, 2018Ĭopyright: © 2018 Lu et al.
Arruda, University of Pennsylvania Perelman School of Medicine, UNITED STATES (2018) Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Citation: Lu G, Pine P, Leeds JM, DeGuzman F, Pratikhya P, Lin J, et al.
0 kommentar(er)
